Repro Med Systems Inc, also known as RMS Medical Products, primarily operates in the medical devices industry. With a focus on innovative medical solutions, RMS specializes in the development, manufacture, and distribution of portable and easy-to-use medical devices. These devices primarily assist with the administration of fluids and medications in various healthcare settings. The company's products, like the Freedom Syringe Infusion System, are designed to enhance patients' quality of life by providing effective and convenient treatment options. As a leader in this industry, Repro Med Systems Inc continues to provide cutting-edge solutions that positively impact healthcare delivery.

The main competitors of Repro Med Systems Inc in the market include other medical device companies such as Becton, Dickinson and Company (BD), Baxter International Inc., and Teleflex Incorporated. These companies also offer a range of medical devices and solutions, competing with Repro Med Systems Inc in the same market segment.

Repro Med Systems Inc, commonly known as RMS Medical Products, is a leading medical device company specializing in the development and commercialization of advanced infusion solutions. With a rich history spanning over 30 years, RMS has established itself as a trusted provider of innovative medical products that improve patient outcomes. The company's flagship product, the FREEDOM Syringe Infusion System, revolutionizes the way medication is delivered, offering patients a convenient and effective alternative to traditional infusion methods. As a pioneer in the industry, Repro Med Systems Inc continues to invest in research and development, ensuring its products remain at the forefront of medical advancements.

Repro Med Systems Inc, a renowned medical device company, has achieved significant milestones throughout its existence. Over the years, the company has successfully developed and marketed innovative medical products, firmly establishing itself as a leader in the industry. Repro Med Systems Inc has gained recognition for its proprietary technology, particularly its market-leading primary product, the FREEDOM60® and FreedomEdge™ Syringe Infusion Systems. These devices have revolutionized the way patients receive medication, offering enhanced convenience, safety, and precision. With a strong commitment to research and development, Repro Med Systems Inc has continually expanded its product portfolio, meeting the evolving needs of healthcare providers and patients alike.

Repro Med Systems Inc, also known as RMS Medical Products, is primarily present in various countries and regions worldwide. The company operates globally, with a significant presence in North America, including the United States and Canada. Additionally, Repro Med Systems Inc has extended its reach to several international markets, such as Europe, particularly in the United Kingdom, Germany, France, Italy, and Spain. Moreover, the company has established a strong presence in the Asia-Pacific region, including Japan, China, and Australia. With its global presence, Repro Med Systems Inc serves a diverse customer base across different continents.

Repro Med Systems Inc, a leading stock in the healthcare sector, represents core values of innovation, excellence, and dedication to patient care. With their robust corporate philosophy, Repro Med Systems Inc strives to provide cutting-edge medical devices and solutions that enhance the quality of life for patients. The company's mission revolves around delivering safe, reliable, and efficient medical technologies, ensuring positive medical outcomes and improving patient experiences. Repro Med Systems Inc's commitment to customer satisfaction, continuous improvement, and ethical business practices truly sets them apart in the industry. By embracing these values, Repro Med Systems Inc establishes itself as a trusted and valued healthcare provider.

Analysts currently set an average price target of 6,73 USD for the KORU Medical Systems stock (median: 7,14 USD), implying +89,6 % versus the latest price. The consensus is based on 11 analyst ratings.

KORU Medical Systems Analyytikkojen kursstavoitteet 2026

11 analysts currently rate the KORU Medical Systems stock: 9 recommend buying, 2 holding and 0 selling. For 2026, analysts expect KORU Medical Systems to generate revenue of 48,69 M USD and earnings per share of −0,04 USD.

KORU Medical Systems Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the KORU Medical Systems share trades at 3,07 EUR (3,55 USD).

The KORU Medical Systems share (KRMD) is listed on 1 stock exchanges, including: NASDAQ (KRMD).

Repro Med Systems Inc (RMS) is a leading provider of medical devices and consumables for infusion and pain therapy. The company was founded in 1980 and is headquartered in Chester, New York. RMS's business model focuses on three main areas: infusion pumps, pain therapy systems, and consumables. One of RMS's key product lines is infusion pumps. The company offers a wide range of portable and stationary infusion pumps used in the administration of fluids and medications to patients. These devices enable accurate dosing and monitoring of infusions, contributing to the safety and effectiveness of treatment. Another important area for RMS is pain therapy. The company offers systems for controlled pain delivery, allowing effective pain relief for patients with acute or chronic pain. RMS provides both portable and stationary pain therapy systems that enable accurate dosing and individual adjustment of pain medications. Consumables such as catheters, syringes, and tubes are also an important part of RMS's offering. The company provides high-quality and reliable products specifically designed for use with their infusion pumps and pain therapy systems. RMS focuses on developing and marketing innovative medical devices and consumables that contribute to the quality and efficiency of patient care. The company works closely with physicians, nurses, and other healthcare providers to understand patient needs and provide the best possible solutions. The company sells its products in the US and worldwide through a network of dealers, distributors, and online platforms. RMS has a strong presence in North America but also operates in Europe, Asia, and other regions. The company places great value on customer satisfaction and offers comprehensive customer support and training. Overall, RMS is an established and successful provider of medical devices and consumables for infusion and pain therapy. The company benefits from a strong market position, innovative products, and an experienced management team. With its broad product line and strong distribution network, RMS is well positioned to continue growing and expanding in the future.

odotettu liikevaihto KORU Medical Systems on 48,69 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto KORU Medical Systems on −2,03 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

KORU Medical Systems:n hinta-voitto-suhde (P/E) on tällä hetkellä −80,68. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan KORU Medical Systems-osakkeen arvostusta.

KORU Medical Systems:n hinta-myynti-suhde (P/S) on tällä hetkellä 3,37. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii KORU Medical Systems-osakkeen arvostuskennuslukuna.

KORU Medical Systems:n Eulpool-laatuscore on 2/10.

KORU Medical Systems:n ISIN on US7599101026. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

KORU Medical Systems:n WKN on 913004. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

KORU Medical Systems:n ticker on KRMD. Tämä pörssinoteeraus käytetään KORU Medical Systems-osakkeiden kauppaan pörssissä.

KORU Medical Systems maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

KORU Medical Systems kuuluu sektoriin 'Terveydenhuolto'.

KORU Medical Systems:n osingot jaetaan valuutassa USD.